LLY

904.44

-0.68%↓

JNJ

233.81

-1.03%↓

ABBV

203.3

-1.4%↓

NVS

146.62

-0.41%↓

AZN

183.22

-0.56%↓

LLY

904.44

-0.68%↓

JNJ

233.81

-1.03%↓

ABBV

203.3

-1.4%↓

NVS

146.62

-0.41%↓

AZN

183.22

-0.56%↓

LLY

904.44

-0.68%↓

JNJ

233.81

-1.03%↓

ABBV

203.3

-1.4%↓

NVS

146.62

-0.41%↓

AZN

183.22

-0.56%↓

LLY

904.44

-0.68%↓

JNJ

233.81

-1.03%↓

ABBV

203.3

-1.4%↓

NVS

146.62

-0.41%↓

AZN

183.22

-0.56%↓

LLY

904.44

-0.68%↓

JNJ

233.81

-1.03%↓

ABBV

203.3

-1.4%↓

NVS

146.62

-0.41%↓

AZN

183.22

-0.56%↓

McKesson Corp

Затворен

СекторЗдравеопазване

870.41 -2.01

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

876.87

Максимум

894.09

Ключови измерители

By Trading Economics

Приходи

40M

1.3B

Продажби

3B

106B

P/E

Средно за сектора

27.246

57.833

Дивидентна доходност

0.33

Марж на печалбата

1.177

Служители

43,000

EBITDA

374M

1.8B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+13.02% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.33%

2.47%

Следващи печалби

7.05.2026 г.

Следваща дата на дивидент

1.04.2026 г.

Следваща дата на екс-дивидент

1.06.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

11B

116B

Предишно отваряне

872.42

Предишно затваряне

870.41

Настроения в новините

By Acuity

50%

50%

144 / 350 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

McKesson Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.03.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23.03.2026 г., 22:55 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23.03.2026 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23.03.2026 г., 23:59 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

23.03.2026 г., 23:59 ч. UTC

Пазарно говорене

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23.03.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23.03.2026 г., 23:37 ч. UTC

Пазарно говорене

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23.03.2026 г., 22:42 ч. UTC

Пазарно говорене
Значими събития в новините

Global Equities Roundup: Market Talk

23.03.2026 г., 22:42 ч. UTC

Пазарно говорене
Значими събития в новините

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23.03.2026 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23.03.2026 г., 22:23 ч. UTC

Пазарно говорене

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23.03.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23.03.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23.03.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23.03.2026 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23.03.2026 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23.03.2026 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23.03.2026 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23.03.2026 г., 22:18 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23.03.2026 г., 22:15 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23.03.2026 г., 22:08 ч. UTC

Пазарно говорене

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23.03.2026 г., 21:42 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

23.03.2026 г., 21:42 ч. UTC

Пазарно говорене

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23.03.2026 г., 21:32 ч. UTC

Печалби

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23.03.2026 г., 21:32 ч. UTC

Печалби

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23.03.2026 г., 21:32 ч. UTC

Печалби

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23.03.2026 г., 21:10 ч. UTC

Значими събития в новините

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

23.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

23.03.2026 г., 20:50 ч. UTC

Пазарно говорене
Печалби
Значими събития в новините

Basic Materials Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

McKesson Corp Прогноза

Ценова цел

By TipRanks

13.02% нагоре

12-месечна прогноза

Среден 991.22 USD  13.02%

Висок 1,107 USD

Нисък 885 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за McKesson Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

9

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

681.92 / 707.28Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

No Evidence

Дългосрочен план

No Evidence

Настроение

By Acuity

144 / 350 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно McKesson Corp

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners, and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
help-icon Live chat